Straits Times Index
3,190.71 -34.64 (-1.07%) S&P 500
3,918.40 -5.28 (-0.13%) Dow
31,363.94 -126.13 (-0.40%) Nasdaq
11,467.64 +49.48 (+0.43%) BTC-USD
30,165.17 +1,188.59 (+4.10%) CMC Crypto 200
671.02 +18.79 (+2.88%)
BELLUS Health Inc. (BLU)
| Previous close | 8.80 |
| Open | 8.78 |
| Bid | 8.78 x 800 |
| Ask | 8.81 x 800 |
| Day's range | 8.64 - 9.01 |
| 52-week range | 2.60 - 9.84 |
| Volume | |
| Avg. volume | 771,572 |
| Market cap | 934.74M |
| Beta (5Y monthly) | -0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.81 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.47 |
- Zacks
Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
- Business Wire
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
LAVAL, Quebec, May 11, 2022--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today reported its financial and operating results for the first quarter ending March 31, 2022.
- Business Wire
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
LAVAL, Quebec, May 02, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference, being held in San
